Hispanic patients also reported better perceptions of communication across all four measures.

Hispanic patients in particular reported less pain relief and had less adequate analgesia.

The prescribing rates were lower than expected, especially in Black and Hispanic patients.

Hispanic patients had the highest rates of open operations.

Hispanic patients were most likely to receive ketorolac only.

Adjuvant hormonal therapy was administered to 6% of the Hispanic patients.

Twenty-three percent of the Hispanic patients received neoadjuvant therapy.

However, Caucasians had the highest prevalence of hyperlipidemia, and the Hispanic patients were the least hypertensive.

To the authors' knowledge, little has been published to date regarding radical prostatectomy in Hispanic patients.

African American and Hispanic patients are more likely to present with associated PAH compared to non-Hispanic whites.

Hispanic patients with PAH were less likely to be treated with PAH-specific medications compared to non-Hispanic whites.

White patients were more likely than either black or Hispanic patients to get the highest opioid dosage.

Sarcopenia was present in 62% of patients and was more likely in female and Hispanic patients.

Background: Hispanic patients with esophageal cancer (EC) have racially disparate survival outcomes compared with white patients.

We retrospectively reviewed charts of African-American and Hispanic patients from January 1994 to December 2005.

Enrollment of ethnic minorities rose by 533%, most significantly for Hispanic patients by 925%.